Revelation Biosciences Inc
Revelation Biosciences, Inc. operates as a clinical-stage biopharmaceutical company that focuses on the development and commercialization of immune system therapeutics and diagnostics. It engages in developing therapeutic product candidates, including GEM-AKI, a potential therapy for the prevention and treatment of acute kidney injury; and GEM-CKD, a potential therapy for the prevention and treat… Read more
Revelation Biosciences Inc (REVB) - Total Assets
Latest total assets as of September 2025: $12.86 Million USD
Based on the latest financial reports, Revelation Biosciences Inc (REVB) holds total assets worth $12.86 Million USD as of September 2025.
Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
Revelation Biosciences Inc - Total Assets Trend (2016–2024)
This chart illustrates how Revelation Biosciences Inc’s total assets have evolved over time, based on quarterly financial data. Explore and compare other companies by total assets.
Revelation Biosciences Inc - Asset Composition Analysis
Current Asset Composition (December 2024)
Revelation Biosciences Inc's total assets of $12.86 Million consist of 99.2% current assets and 0.9% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 98.1% |
| Accounts Receivable | $0.00 | 0.0% |
| Inventory | $0.00 | 0.0% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $0.00 | 0.0% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (2016–2024)
This chart illustrates how Revelation Biosciences Inc's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Revelation Biosciences Inc's current assets represent 99.2% of total assets in 2024, an increase from 0.0% in 2016.
- Cash Position: Cash and equivalents constituted 98.1% of total assets in 2024, up from 5.9% in 2016.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, a decrease from 1.0% in 2016.
- Asset Diversification: The largest asset category is goodwill at 0.0% of total assets.
Revelation Biosciences Inc Competitors by Total Assets
Key competitors of Revelation Biosciences Inc based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
MedPacto Inc
KQ:235980
|
Korea | ₩51.58 Billion |
|
2H0
F:2H0
|
Germany | €15.27 Million |
|
Shenzhen CAU Technology Co Ltd
SHE:000004
|
China | CN¥260.55 Million |
|
Pacific Shuanglin Bio pharmacy Co Ltd
SHE:000403
|
China | CN¥9.58 Billion |
|
Nanhua Bio Medicine Co Ltd
SHE:000504
|
China | CN¥841.96 Million |
|
Jiangsu Sihuan Bioengineering Co Ltd
SHE:000518
|
China | CN¥509.14 Million |
|
Chengzhi Shareholding Co Ltd
SHE:000990
|
China | CN¥27.52 Billion |
|
Hualan Biological EngineeringInc
SHE:002007
|
China | CN¥16.27 Billion |
Revelation Biosciences Inc - Asset Efficiency Metrics
Asset efficiency metrics measure how effectively a company uses its assets to generate revenue and profits. These indicators help investors evaluate management's ability to deploy capital efficiently.
Asset Turnover Ratio
Measures how efficiently a company uses its assets to generate sales
Lower asset utilization - Revelation Biosciences Inc generates 0.00x its asset value in annual revenue.
Return on Assets (ROA)
Measures how efficiently a company uses its assets to generate profits
Negative ROA - Revelation Biosciences Inc is currently not profitable relative to its asset base.
Revelation Biosciences Inc - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 6.92 | 1.64 | 1.35 |
| Quick Ratio | 6.92 | 1.64 | 1.35 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $10.98 Million | $ 2.59 Million | $ 1.19 Million |
Revelation Biosciences Inc - Advanced Valuation Insights
This section examines the relationship between Revelation Biosciences Inc's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 0.35 |
| Latest Market Cap to Assets Ratio | 0.26 |
| Asset Growth Rate (YoY) | -45.8% |
| Total Assets | $6.62 Million |
| Market Capitalization | $1.72 Million USD |
Valuation Analysis
Below Book Valuation: The market values Revelation Biosciences Inc's assets below their book value (0.26 x), which may indicate investor concerns about asset quality or future growth.
Significant Asset Reduction: Revelation Biosciences Inc's assets decreased by 45.8% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for Revelation Biosciences Inc (2016–2024)
The table below shows the annual total assets of Revelation Biosciences Inc from 2016 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | $6.62 Million | -45.78% |
| 2023-12-31 | $12.21 Million | +121.91% |
| 2022-12-31 | $5.50 Million | +169.48% |
| 2021-12-31 | $2.04 Million | -55.80% |
| 2020-12-31 | $4.62 Million | +20280.22% |
| 2019-12-31 | $22.67K | -100.00% |
| 2018-12-31 | $2.46 Billion | +16.98% |
| 2017-12-31 | $2.10 Billion | +10.80% |
| 2016-12-31 | $1.89 Billion | -- |